Frontage Laboratories Inc.
For more than two decades, BRI (a wholly owned subsidiary of Frontage Laboratories) is engaged in providing science-driven drug discovery and IND/NDA-enabling studies for pharmaceutical and biotechnology companies.
As a CRO, BRI offers a variety of services to its customer base, including but not limited to bioanalytical assays for measurement of drug candidates, metabolites and biomarkers, in-vitro drug metabolism/ADME, in vivo DMPK/ADME, formulation development, DS/DP stability and
analytical CMC assays, human tumor xenograft mouse efficacy models, obesity/diabetes rodent metabolic disease models, and human gut microbiome metabolism and biomarker assays.
BRI’s uncompromising study protocols, stringent quality control measures, and relevant study design allows them to build trusted and long lasting partnerships with their highly valued clients.
Contract Research & Scientific Services, Lab Services
- Analytical Services
- Animal Modeling
- Bioanalytical Services
- cGMP/GLP Compliance
- Contract Manufacturing
- Diabetes
- Drug Discovery
- Metabolic Diseases
- Microbiome
- Oncology
- Pre-Clinical Services
- Product Development
- Regulatory
- Therapeutics
- Toxicology
Contract Research & Scientific Services , Lab Services
We are focused on helping our clients address their most significant and complex drug discovery and development challenges. Our scientific knowledge base, technical expertise and reputation for high quality services have been integral to our ability to turn our services into your solutions.
Member Profile
Contract Research & Scientific Services, Lab Services
Frontage Laboratories Inc.
- Website www.frontagelab.com
- Phone +1 (604) 432 9237
- Email bri_info@frontagelab.com
- Address
101 - 8898 Heather Street
Vancouver, BC
V6P 3S8 - Leadership Contact
Martin Poirier, Executive Director and Site Head